Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of Abiomed, Inc.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims against Abiomed, Inc. (“Abiomed” or the “Company”) (NASDAQ:ABMD) concerning possible violations of federal securities laws. The investigation focuses on allegations that certain statements issued by the Company regarding Abiomed’s business, operations and financial condition were false and misleading.

Abiomed is a provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Specifically, the investigation relates to Abiomed’s November 1, 2012 disclosure that on October 26, 2012 the Company was informed that the United States Attorney’s Office for the District of Columbia was conducting an investigation into Abiomed’s marketing and labeling of its Impella 2.5 system, and that on October, 31, 2012 Abiomed accepted service of a Health Insurance Portability and Accountability Act administrative subpoena related to this investigation. On this news, shares of Abiomed declined $6.31 per share, or 31.33%, to close on November 1, 2012 at $13.61 per share, on heavy trading volume.

If you purchased Abiomed securities, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], Toll Free at [phone], or by email to [e-mail], or visit our website at http://www.howardsmithlaw.com.